9.21
Schlusskurs vom Vortag:
$9.88
Offen:
$9.58
24-Stunden-Volumen:
21,030
Relative Volume:
0.09
Marktkapitalisierung:
$8.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.93M
KGV:
-0.0346
EPS:
-266.137
Netto-Cashflow:
$-15.87M
1W Leistung:
+3.37%
1M Leistung:
+7.85%
6M Leistung:
-20.53%
1J Leistung:
-96.91%
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Firmenname
Transcode Therapeutics Inc
Sektor
Branche
Telefon
857-301-6857
Adresse
6 LIBERTY SQUARE, BOSTON
Compare RNAZ vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
RNAZ
Transcode Therapeutics Inc
|
9.21 | 9.06M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Transcode Therapeutics Inc Aktie (RNAZ) Neueste Nachrichten
Can TransCode Therapeutics Inc. sustain its profitability2025 Major Catalysts & Intraday High Probability Setup Alerts - mfd.ru
Why is TransCode Therapeutics Inc. stock going downMarket Sentiment Review & Weekly High Conviction Ideas - mfd.ru
Movement Recap: Is TransCode Therapeutics Inc showing insider buyingWeekly Trade Analysis & Community Consensus Trade Alerts - baoquankhu1.vn
Aug Selloffs: Will TransCode Therapeutics Inc benefit from geopolitical trendsProfit Target & Smart Investment Allocation Insights - baoquankhu1.vn
Can TransCode Therapeutics Inc. disrupt its industryPortfolio Update Report & AI Powered Buy and Sell Recommendations - mfd.ru
What’s the beta of TransCode Therapeutics Inc. stockJuly 2025 Sentiment & Daily Stock Trend Watchlist - mfd.ru
Big Money Moves: Whats the beta of TransCode Therapeutics Inc stockWeekly Stock Recap & Trade Opportunity Analysis - baoquankhu1.vn
TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial - TechStock²
Therapeutics, Inc. (RNAZ) Stock: Jumps as Company Expands RNA Cancer Program into Colorectal Indication - parameter.io
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
TransCode Therapeutics Unveils Promising Glioblastoma Data with TTX-MC138 - timothysykes.com
TransCode Therapeutics’ TTX-MC138 Excites Market with Promising Glioblastoma Data - StocksToTrade
TransCode Therapeutics: Promising Data Boosts Future Outlook - timothysykes.com
TransCode Therapeutics Advances Phase 2a Colorectal Cancer Trial - TipRanks
TransCode Therapeutics Announces IND Amendment for Phase 2a Trial - TradingView
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial With TTX-MC138 - 富途牛牛
Gainers Report: Does TransCode Therapeutics Inc have pricing powerRisk Management & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Aug Gainers: Why is TransCode Therapeutics Inc stock going downCPI Data & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Risk Analysis: Whats the beta of TransCode Therapeutics Inc stockJuly 2025 Spike Watch & Smart Allocation Stock Reports - baoquankhu1.vn
Aug Intraday: What’s the beta of TransCode Therapeutics Inc. stock2025 Trading Recap & Free Weekly Watchlist of Top Performers - mfd.ru
What are analysts’ price targets for TransCode Therapeutics Inc.July 2025 Patterns & Entry Point Strategy Guides - mfd.ru
Earnings Recap: Is TransCode Therapeutics Inc a good stock for dollar cost averagingPortfolio Performance Summary & Weekly Breakout Watchlists - baoquankhu1.vn
Market Recap: Is TransCode Therapeutics Inc a good stock for dollar cost averagingJuly 2025 PostEarnings & Stepwise Trade Signal Guides - baoquankhu1.vn
Short Squeeze: Should I hold or sell TransCode Therapeutics Inc nowJuly 2025 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn
Market Catalysts: Is TransCode Therapeutics Inc a speculative investmentQuarterly Portfolio Report & Fast Gain Swing Alerts - baoquankhu1.vn
Entry Recap: How does OLPX compare to its peersWeekly Profit Summary & Growth Focused Stock Pick Reports - baoquankhu1.vn
Is TransCode Therapeutics Inc. stock in correction or buying zone2025 Volume Leaders & High Yield Equity Trading Tips - bollywoodhelpline.com
Options Flow: Does TransCode Therapeutics Inc have pricing powerJuly 2025 Earnings & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Fundamentals Check: Is TransCode Therapeutics Inc attractive for institutional investors2025 Trade Ideas & AI Based Buy and Sell Signals - baoquankhu1.vn
Bull Bear: What are analysts price targets for TransCode Therapeutics IncJuly 2025 Pullbacks & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Market Recap: What are analysts price targets for TransCode Therapeutics IncJuly 2025 Technicals & Reliable Price Breakout Alerts - baoquankhu1.vn
Will TransCode Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Gainers & AI Powered Market Entry Strategies - Улправда
MSN Money - MSN
Is TransCode Therapeutics Inc. stock attractive for income investorsBreathability and Upper Notes & HOKA model picks for your routine - ulpravda.ru
Will TransCode Therapeutics Inc. stock split again soonJuly 2025 Closing Moves & Weekly High Return Stock Opportunities - Улправда
Why retail investors pile into TransCode Therapeutics Inc. stockWeekly Trade Review & Reliable Entry Point Alerts - Улправда
TransCode Therapeutics, Inc.Common Stock (NQ: RNAZ - FinancialContent
Can TransCode Therapeutics Inc. stock double in next 5 years2025 Volatility Report & Risk Managed Trade Strategies - Улправда
TransCode’s glioblastoma therapy shows promise in preclinical study By Investing.com - Investing.com Nigeria
(RNAZ) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
How TransCode Therapeutics Inc. stock benefits from tech adoption2026 world cup usa national team quarterfinals midfield engines counter attacking knockout prediction tactical review - ulpravda.ru
TransCode Therapeutics Publishes Preclinical Data Supporting TTX-MC138 for Glioblastoma Treatment - citybuzz -
Transcode Therapeutics Ttx-Mc138 phase 2a clinical trial expected in first half of 2026 - marketscreener.com
Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026 - TradingView — Track All Markets
TransCode Therapeutics reports promising preclinical glioblastoma results - TipRanks
TransCode Therapeutics stock soars after promising glioblastoma study By Investing.com - Investing.com Canada
TransCode Therapeutics Publishes Preclinical Data on TTX-MC138 for Glioblastoma - TradingView — Track All Markets
TransCode’s glioblastoma therapy shows promise in preclinical study - Investing.com
Experimental RNA therapy extends survival in brain cancer animal tests - Stock Titan
TransCode reports positive phase 1 trial progress for cancer therapy - MSN
Precision Trading with Transcode Therapeutics Inc. (RNAZ) Risk Zones - Stock Traders Daily
Finanzdaten der Transcode Therapeutics Inc-Aktie (RNAZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):